---
title: 'Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate
  cancer (WARMTH Act): a multicentre, retrospective study'
date: '2024-01-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38218192/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240114170712&v=2.18.0
source: heidelberg[Affiliation]
description: 'BACKGROUND: Actinium-225 (^(225)Ac) prostate-specific membrane antigen
  (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant
  prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of
  ^(225)Ac-PSMA RLT of mCRPC in a large cohort of patients treated at multiple centres
  across the ...'
disable_comments: true
---
BACKGROUND: Actinium-225 (^(225)Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of ^(225)Ac-PSMA RLT of mCRPC in a large cohort of patients treated at multiple centres across the ...